Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
350
ISIN
US40637H1095
Website
HALO Metrics
BasicAdvanced
$6.5B
13.98
$3.76
1.18
-
Price and volume
Market cap
$6.5B
Beta
1.18
52-week high
$70.51
52-week low
$42.01
Average daily volume
2.2M
Financial strength
Current ratio
8.392
Quick ratio
6.999
Long term debt to equity
312.573
Total debt to equity
312.573
Interest coverage (TTM)
32.99%
Profitability
EBITDA (TTM)
673.223
Gross margin (TTM)
77.62%
Net profit margin (TTM)
44.76%
Operating margin (TTM)
55.10%
Effective tax rate (TTM)
19.77%
Revenue per employee (TTM)
$3,100,000
Management effectiveness
Return on assets (TTM)
18.49%
Return on equity (TTM)
147.06%
Valuation
Price to earnings (TTM)
13.975
Price to revenue (TTM)
6.099
Price to book
13.42
Price to tangible book (TTM)
-20.31
Price to free cash flow (TTM)
13.34
Free cash flow yield (TTM)
7.50%
Free cash flow per share (TTM)
393.78%
Growth
Revenue change (TTM)
25.65%
Earnings per share change (TTM)
55.39%
3-year revenue growth (CAGR)
31.99%
10-year revenue growth (CAGR)
29.45%
3-year earnings per share growth (CAGR)
7.82%
10-year earnings per share growth (CAGR)
23.43%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
Bulls say / Bears say
Halozyme's ENHANZE® technology has been integrated into multiple FDA-approved therapies, including Roche's Tecentriq Hybreza™ and Bristol Myers Squibb's Opdivo Qvantig™, enhancing drug delivery and patient convenience. (prnewswire.com)
The company reported a 34% year-over-year increase in total revenue to $290 million in Q3 2024, with net income rising by 67% to $137 million, indicating strong financial performance. (prnewswire.com)
Analysts have set an average 12-month price target of $67.50 for Halozyme, suggesting a potential upside of approximately 9.95% from the current stock price. (tipranks.com)
Halozyme is engaged in a patent dispute with Merck over the subcutaneous formulation of Keytruda, which could lead to costly litigation and potential revenue loss. (reuters.com)
Renaissance Technologies LLC significantly reduced its holdings in Halozyme by 89.8%, selling 229,170 shares, which may indicate decreased confidence from institutional investors. (marketbeat.com)
Analysts have issued mixed ratings, with some downgrading the stock to 'neutral' and adjusting price targets, reflecting uncertainty about future growth prospects. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $6.5B as of June 28, 2025.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 13.98 as of June 28, 2025.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.